Advancement of clinical practice in delivering CAR T-cell therapy: impact on healthcare resource utilization and comparison with autologous stem cell transplantation in patients with relapsed/refractory large B-cell lymphomas.

Martin Fehr, Matthias Naegele, Michael Greiling

Abstract readComparative Study

In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Martin FehrDepartment of Medical Oncology and Haematology, Cantonal Hospital St. Gallen/HOCH Health Ostschweiz, St. Gallen, Switzerland. Martin.Fehr@h-och.ch.ORCID http://orcid.org/0000-0003-2128-9061

Matthias NaegeleDepartment of Medical Oncology and Haematology, Cantonal Hospital St. Gallen/HOCH Health Ostschweiz, St. Gallen, Switzerland.ORCID http://orcid.org/0000-0003-3169-1812

Michael GreilingInstitute for Workflow-Management in Health Care, European University of Applied Sciences, Cologne, Germany.ORCID http://orcid.org/0000-0002-3449-5123

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) who are either refractory to first-line therapy or relapse within 12 months, chimeric antigen receptor (CAR) T-cell therapy is more effective than salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT) as second-line therapy. Adoption of CAR T-cell therapy into routine clinical practice involves a period of adaptation and refinement of clinical processes. We aimed to document the evolution of clinical processes for CAR T-cell therapy during 2022 and 2023, and compare healthcare resource utilization (HCRU) associated with CAR T-cell and ASCT processes in routine clinical practice. ClipMed

Indexed as

Hematopoietic Stem Cell TransplantationImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffusePatient Acceptance of Health CareAdultFemaleHumansMaleMiddle AgedReceptors, Chimeric AntigenRecurrenceTransplantation, AutologousReceptors, Chimeric AntigenASCTCAR T-cellHealthcare resource utilizationLarge B-cell lymphoma

Identifiers

PMID40913623

DOI10.1007/s00277-025-06564-y

PMCPMC12552251

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.